Adopting cutting-edge technology is playing a vital role now more than ever in the digital revolution of the pharmaceutical industry, with any advancement that may offer improvement quickly becoming a big focus.

World-leading A-Z service companies such as QUINTA-ANALYTICA are constantly adopting more tech and embracing new technologies that are proving critical to revolutionizing research, attracting patients for trials, and reducing the speed of delivering results.

Technologies like Artificial Intelligence (AI), Machine Learning (ML), and digital apps, are allowing pharmaceutical companies to not only improve their access to vital medical and patient information but improve their accuracy and capability.

With AI already being used in the healthcare industry while conducting repetitive tasks such as data entry, lab test analyses, and data management to identify errors or inefficiencies, and ML being used in disease identification and diagnosis, clinical trial research, and new drug invention, it’s clear that tech is ingrained in an irreversible way.

Further used to improve operational, regulatory, and financial performance, the answer is certain that in modern companies like Quinta, tech undoubtedly helps pharma.

Additional News

  • 7 August 2026

    Quinta-Analytica at CPHI Milan 2026 – Meet Us at Conscio Group Stand 6N25

    Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.